Strategic acquisition expands Boston Scientific’s urology portfolio with advanced sacral neuromodulation solutions.
Boston Scientific (NYSE: BSX) has finalized its $3.7 billion acquisition of Axonics, Inc. (Nasdaq: AXNX), adding Axonics’ sacral neuromodulation (SNM) systems and urethral bulking agent to its urology offerings.
Enhancing Urology and Pelvic Health Solutions
Axonics’ innovative SNM systems, including the rechargeable R20 and recharge-free F15, treat urinary and bowel dysfunction through mild electrical pulses. The Bulkamid agent offers additional treatment for stress urinary incontinence.
“This acquisition allows us to expand into sacral neuromodulation, bringing tailored options to patients worldwide,” said Meghan Scanlon, Boston Scientific’s SVP of Urology.
Strategic Growth Through M&A
Boston Scientific’s focus on mergers and acquisitions continues to drive innovation and growth. Axonics’ 27% market share in the underpenetrated SNM segment complements Boston Scientific’s pelvic health solutions, challenging the dominance of Medtronic.
Leadership Transition and Financial Impact
Axonics’ leadership structure transitioned, with Boston Scientific executives assuming key roles. The acquisition is projected to have a minimal impact on adjusted earnings per share through 2025, with accretion expected in later years.
With Axonics’ cutting-edge technology, Boston Scientific solidifies its leadership in urology and pelvic health medtech.
Follow MEDWIRE.AI for the latest updates on MedTech acquisitions and innovations.
